Cardiac CT scanner receives FDA clearance

Hegseth orders testosterone testing for troops as FDA moves to loosen TRT prostate cancer warnings
Experts caution the move amounts to a “huge, unregulated, natural experiment”

In a video captioned “The High-T Department of War” and posted on X, Secretary of Defense Pete Hegseth announced that he was authorizing a screening program for troops to ensure “you have the right testosterone levels to operate at your absolute best.”

July 24, 2026

Vol.52 No.29

By Claire Marie Porter

Guest Editorial

The Susan Wojcicki Foundation pushes for rethinking of strategies for early lung cancer detection

The Susan Wojcicki Foundation, a new entrant into health philanthropy, is taking on a critical mission: Advancing research into new approaches to early detection of lung cancer—redefining risk, expanding awareness, and accelerating innovation.

Biological sex linked to protein changes in lung adenocarcinoma and other cancers, Sanford Burnham Prebys study finds

Biological sex factors into cancer in ways you might not expect. In lung cancer, a form called squamous cell carcinoma disproportionately affects males while adenocarcinoma occurs more frequently in females.

July 24, 2026

Vol.52 No.29

Drugs & Targets

FDA approves Jideytro for previously treated ROS1-positive non-small cell lung cancer

FDA approved Jideytro (zidesamtinib), a ROS1 selective inhibitor, for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer who received a prior ROS1 kinase inhibitor.

July 24, 2026

Vol.52 No.29

Drugs & Targets

FDA grants priority review for Talzenna + Xtandi combo in earlier prostate cancer

FDA accepted for Priority Review a supplemental New Drug Application for Talzenna (talazoparib), an oral poly ADP-ribose polymerase inhibitor, in combination with Xtandi (enzalutamide), an androgen receptor pathway inhibitor, in men with homologous recombination repair gene-altered metastatic castration-sensitive prostate cancer, also known as metastatic hormone-sensitive prostate cancer.

July 24, 2026

Vol.52 No.29

Podcast

How will FDA regulate psychedelics?

FDA has been taking a look at psychedelics as a potential treatment for psychiatric and substance abuse disorders, recently publishing a final guidance for drug sponsors conducting clinical trials of psychedelics, including psilocybin, LSD, and MDMA.

July 22, 2026

Vol.52 No.28

Cardiac CT scanner receives FDA clearance

YOU MAY BE INTERESTED IN

Hegseth orders testosterone testing for troops as FDA moves to loosen TRT prostate cancer warnings
Experts caution the move amounts to a “huge, unregulated, natural experiment”

The Susan Wojcicki Foundation pushes for rethinking of strategies for early lung cancer detection

Biological sex linked to protein changes in lung adenocarcinoma and other cancers, Sanford Burnham Prebys study finds

FDA approves Jideytro for previously treated ROS1-positive non-small cell lung cancer

FDA grants priority review for Talzenna + Xtandi combo in earlier prostate cancer

How will FDA regulate psychedelics?

Renew today!

Subscriber content

Never miss an issue!

Login

Cardiac CT scanner receives FDA clearance

YOU MAY BE INTERESTED IN

Hegseth orders testosterone testing for troops as FDA moves to loosen TRT prostate cancer warningsExperts caution the move amounts to a “huge, unregulated, natural experiment”

The Susan Wojcicki Foundation pushes for rethinking of strategies for early lung cancer detection

Biological sex linked to protein changes in lung adenocarcinoma and other cancers, Sanford Burnham Prebys study finds

FDA approves Jideytro for previously treated ROS1-positive non-small cell lung cancer

FDA grants priority review for Talzenna + Xtandi combo in earlier prostate cancer

How will FDA regulate psychedelics?

Never miss an issue!

Login

Hegseth orders testosterone testing for troops as FDA moves to loosen TRT prostate cancer warnings
Experts caution the move amounts to a “huge, unregulated, natural experiment”